...endpoint of improving median OS vs. placebo plus BSC (20.3 vs. 17.8 months, HR=0.94, p=0.594). NovaRx...
...European Cancer Congress in Amsterdam. Lucanix has Fast Track designation in the U.S. for NSCLC. NovaRx Corp....

...who have responded to, or have stable disease following one regimen of, first-line platinum-based chemotherapy. NovaRx...
...p=0.083). Data will be presented at the European Cancer Congress in Amsterdam on Sept. 28. NovaRx...

...nitroglycerin lingual spray Angina pectoris due to coronary artery disease (CAD) Submit regulatory application 2H12 NovaRx Corp....

...III data events expected over the next couple of years include Kael-Gemvax Co. Ltd. ; NovaRx Corp....
...another Phase III trial is evaluating the product in advanced non-small cell lung cancer (NSCLC). NovaRx's...
...Gaithersburg, Md. Memorial Sloan-Kettering Cancer Center , New York, N.Y. Merck KGaA (Xetra:MRK), Darmstadt, Germany NovaRx Corp....

...Hired: Norrie Russell as president of Ocimum's Gene Logic subsidiary, formerly president and COO of NovaRx Corp. WIR...

...to be eligible for enrollment. Lucanix has Fast Track designation in the U.S. for NSCLC. NovaRx Corp....

...with Affitech A/S) GV1001 Vaccine targeting human telomerase reverse transcriptase (hTERT) Pancreatic cancer Ph III NovaRx Corp....

...Cancer company NovaRx (San Diego, Calif.) hired Norrie Russell as president and COO. Previously, he was...
...as president and COO. Previously, he was president and CEO of Kalos (San Diego, Calif.). NovaRx...

...disease after a platinum-based chemotherapeutic. Lucanix has Fast Track designation in the U.S. for NSCLC. NovaRx Corp....